Salvador
Martín Algarra
Consultor Médico
Institut Universitari Dexeus
Barcelona, EspañaPublikationen in Zusammenarbeit mit Forschern von Institut Universitari Dexeus (10)
2024
-
Access to melanoma drugs in Spain: a cross-sectional survey
Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583
-
Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis
Clinical and Translational Oncology
2023
-
SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry
Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 768-775
2018
-
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
Annals of Oncology, Vol. 29, Núm. 10, pp. 2121-2128
-
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
Therapeutic Advances in Medical Oncology, Vol. 10
2017
-
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program
Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 761-768
2016
-
Circulating melanoma exosomes as diagnostic and prognosis biomarkers
Clinica Chimica Acta, Vol. 454, pp. 28-32
2015
-
BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors
Melanoma Research, Vol. 25, Núm. 6, pp. 486-495
-
Frequency and characteristics of familial melanoma in Spain: The FAM-GEM-1 study
PLoS ONE, Vol. 10, Núm. 4
-
Immune checkpoint inhibitors: Therapeutic advances in melanoma
Annals of Translational Medicine, Vol. 3, Núm. 18